Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05242835

Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery

Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question.

Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies.

With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Universitaire de Cardiologie et de Pneumologie de Québec

Québec, Quebec, G1V 4G5, Canada

Location status: Recruiting

Location contact

Andreanne Michaud, PhD

SUB_INVESTIGATOR

André Tchernof, PhD

SUB_INVESTIGATOR

Caroline Diorio, PhD

SUB_INVESTIGATOR

Laurent Biertho, MD

PRINCIPAL_INVESTIGATOR

Suzy Laroche

CONTACT

[email protected]

418-656-8711 ext. 3841

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • had sleeve gastrectomy a minimum of 18 months before
  • still meet the NIH criteria for bariatric surgery (BMI≥35kg/m2 with major comorbidities or BMI≥40kg/m2) or patients with EWL<50% or significant weight regain (≥20%EWL)

Exclusion criteria

  • general contra-indication for bariatric surgery
  • BMI<35kg/m2
  • pregnancy
  • cirrhosis
  • abnormal bowel habits including irritable bowel syndrome and inflammatory bowel disease

Treatment and study plan

Standard duodenal switch

Procedure

Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)

Other names: BPD-DS

Single-anastomosis duodenal switch

Procedure

Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)

Other names: SADI

Primary outcomes

  1. Excess weight loss

    Time frame: 12 month

    Percentage of excess weight loss mobilized in response to surgery

Secondary outcomes

  1. Peroperative complications

    Time frame: from baseline up to 60 months

    Complications graded with Clavien classification

  2. Risk of malnutrition

    Time frame: from baseline to 60 months

    Risk of malnutrition assessed through measurement of its risk being mild (albumin<35g\\L), moderate (albumin<30g/L) or severe (albumin<25g/L)

  3. Change in quality of life (SF-36)

    Time frame: from baseline to 60 months

    36-item short form survey evaluating quality of life on a scale form 0 to 100

  4. Change in quality of life (BAROS)

    Time frame: from baseline to 60 months

    Bariatric Analyses and Reporting Outcomes System score form -7 to 9

  5. Change in quality of life (QLaval)

    Time frame: from baseline to 60 months

    Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7

  6. Gastro-intestinal side effects

    Time frame: from baseline to 60 months

    Evaluation of gastro-intestinal side effects with the Gastro-Intestinal Quality of Life Index from 0 to 144

  7. Change in nutritional status (calcium)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis of calcium (mmol/L)

  8. Change in nutritional status (ferritin)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis of ferritin (ug/L)

  9. Change in nutritional status (TIBC)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis of TIBC (umol/L)

  10. Change in nutritional status (iron)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis of iron (umol/L)

  11. Change in nutritional status (prealbumin)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis of prealbumin (g/L)

  12. Change in nutritional status (transferrin)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis transferrin (g/L)

  13. Change in nutritional status (vitamin A)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis of vitamin A (umol/L)

  14. Change in nutritional status (vitamin D3)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis of vitamin D3 (nmol/L)

  15. Change in nutritional status (parathormone)

    Time frame: from baseline to 60 months

    Change in nutritional status based on blood analysis parathormone (ng/L)

  16. Change in food intake

    Time frame: from baseline to 60 months

    Evaluation of the change in food intake using a web-based food frequency questionnaire (kcal/day)

  17. Change in eating behavior

    Time frame: from baseline to 60 months

    Change of eating behavior using the Three-Factor Eating Questionnaire evaluating cognitive restraint of eating on a scale from 0 to 20, disinhibition on a scale from 0 to 16 and hunger on a scale from 0 to 15

  18. Change in food addiction

    Time frame: from baseline to 60 months

    Change of eating behavior using the Yale Food Addiction Scale that includes a "symptom count" scale from 0 to 7 reflecting the number of addiction-like criteria endorsed and a dichotomous evaluation that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met

  19. Change in binge eating behavior

    Time frame: from baseline to 60 months

    Change of eating behavior using the Binge Eating scale from 0 to 46

  20. Evolution of obesity related diseases

    Time frame: from baseline to 60 months

    Remission rate for comorbidities, including T2D, hypertension, dyslipidemia, sleep apnea according to the ASMBS definition of outcomes reporting

Study contacts

Contact information is provided by the study sponsor or research team.

Mélanie Nadeau, MSc

CONTACT

[email protected]

418-656-8711 ext. 3490

Suzy Laroche

CONTACT

[email protected]

418-656-8711 ext. 3841

Sponsors and collaborators

Lead sponsor

Laval University

Other

Collaborators

  • Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Feb 16, 2022
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.